The BTK Inhibitor CC-292 shows activity in Mantle Cell Lymphoma and synergizes with Lenalidomide and NIK Inhibitors depending on NFκB mutational status. Homo sapiens
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA369382
下载链接
链接失效反馈官方服务：
资源简介：
Mantle Cell lymphoma (MCL) were treated with the BTK inhibitor 1mM CC-292 for 48h We used microarrays to uncover the mechanisms underlying CC-292 activity in Mantle Cell lymphoma (MCL) Overall design: Global RNA expression was done in two MCL cell lines treated in vitro with CC-292 for 48h
创建时间：
2017-01-31
